iGlarLixi and Residual Hyperglycaemia in Chinese Adults With Type 2 Diabetes on Basal Insulin: A Post Hoc Analysis
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
